Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications; during stability testing
| Brand name | BUPROPION HYDROCHLORIDE |
| Generic name | BUPROPION HYDROCHLORIDE |
| Active ingredient(s) | BUPROPION HYDROCHLORIDE |
| Distributed by / for | Sun Pharmaceutical Industries, Inc., Cranbury, NJ |
| NDC | 47335-737-86 |
| Full product label | buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86 |
| Recalling firm | SUN PHARMACEUTICAL INDUSTRIES INC |
| Distribution | Nationwide in the U.S.A |
| Quantity | 5,344 Bottles |
| Recall initiated | 2023-05-09 |
| Report date | 2023-05-31 |
| Recall completed | 2024-02-27 |
| Recall number | D-0761-2023 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Princeton NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗